Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Perjeta
Perjeta
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Roche
Perjeta
Herceptin
HER2+ breast cancer
SABCS
breast cancer
Flag link:
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Flag link:
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
Pharmaforum
Roche
Perjeta
Herceptin
Genentech
HER2-positive breast cancer
Flag link:
Roche snags another Perjeta combo nod, but will 'weak' data limit its use?
Roche snags another Perjeta combo nod, but will 'weak' data limit its use?
Fierce Pharma
Roche
Perjeta
breast cancer
Flag link:
Drug developers face increasingly risky tightrope walk between top-line results and hard data
Drug developers face increasingly risky tightrope walk between top-line results and hard data
Endpoints
drug development
clinical trials
late stage data
Roche
Perjeta
Flag link:
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
Motley Fool
Roche
Tecentriq
Perjeta
HER-2 postive breast cancer
Ocrevus
MS
multiple sclerosis
diagnostics
generics
biosimilars
Flag link:
Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug
Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug
Endpoints
Roche
Mylan Labs
Herceptin
Perjeta
breast cancer
Flag link:
Roche shares spike as PhIII breast cancer combo with Perjeta scores a success, Puma takes a beating
Roche shares spike as PhIII breast cancer combo with Perjeta scores a success, Puma takes a beating
Endpoints
Roche
breast cancer
clinical trials
Perjeta
Flag link:
Roche Has Aphinity For Perjeta Trial Success, But Not Puma
Roche Has Aphinity For Perjeta Trial Success, But Not Puma
Seeking Alpha
Roche
Perjeta
Puma Biotechnology
breast cancer
Flag link:
A Look at Roche’s Potential Revenue Drivers
A Look at Roche’s Potential Revenue Drivers
Market Realist
Roche
Perjeta
Herceptin
Kadcyla
Flag link:
Inside Roche’s Next Oncology Portfolio Drivers
Inside Roche’s Next Oncology Portfolio Drivers
Yahoo/Market Realist
Roche
oncology
Kadcyla
Perjeta
T-DM1. breast cancer
Flag link:
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Fierce Pharma Marketing
biosimilars
AbbVie
Roche
Amgen
Rituxan
Herceptin
Avastin
Neupogen
Neulasta
Epogen
Humira
Perjeta
Gazyva
Flag link:
Roche's Perjeta increases survival in late-stage breast cancer study
Roche's Perjeta increases survival in late-stage breast cancer study
First Word Pharma
Roche
Perjeta
breast cancer
Herceptin
Flag link:
Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla
Roche's breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla
Fierce Pharma
Roche
breast cancer
Perjeta
Kadcyla
earnings
Flag link:
PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative
PDL Biopharma: Agreement With Genentech And Roche Is A Net Negative
Seeking Alpha
PDL Biopharma
Roche
Genentech
Avastin
Herceptin
Lucentis Xolair
Kadcyla
Perjeta
Lucentis
Flag link:
PDL Biopharma says it settled Roche royalty fight
PDL Biopharma says it settled Roche royalty fight
Yahoo/AP
PDL Biopharma
Roche
Avastin
Herceptin
Kadcyla
Perjeta
Lucentis
Xolair
Flag link:
FDA Approval Of Roche Cancer Drug Signals A New Paradigm
FDA Approval Of Roche Cancer Drug Signals A New Paradigm
Pharmalot
Roche
drug approvals
FDA
Perjeta
Flag link:
Roche breast cancer drug gets expanded U.S. pre-surgery approval
Roche breast cancer drug gets expanded U.S. pre-surgery approval
Reuters
Roche
FDA
breast cancer
Perjeta
Flag link:
Roche Perjeta Wins Panel Backing for Early Breast Cancer
Roche Perjeta Wins Panel Backing for Early Breast Cancer
Bloomberg
Roche
Perjeta
breast cancer
FDA
advisory panels
Flag link:
FDA scientists back accelerated approval for Roche drug to treat early-stage breast cancer
FDA scientists back accelerated approval for Roche drug to treat early-stage breast cancer
Washington Post, DC
Perjeta
FDA
Roche
breast cancer
Flag link:
Pages
1
2
next ›
last »